- Zacks•5 hours ago
Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.
- Investor's Business Daily•21 hours ago
Merck and Roche are swiping share from Bristol-Myers Squibb's I-O drugs after their FDA approvals in advanced lung cancer.
- Insider Monkey•22 hours ago
Bristol-Myers Squibb Co (NYSE:BMY) will sell senior notes that are unsecured worth $1.5 billion. Half of that amount is due in two years at a rate of 1.6% while the other half is due in a decade at a rate of 3.25%. The offering will be jointly managed by various investment banks and firms including […]
BMY : Summary for Bristol-Myers Squibb Company Co - Yahoo Finance
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||55.88 - 56.21|
|52 Week Range||46.01 - 77.12|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.19|
|Dividend & Yield||1.56 (2.82%)|
|1y Target Est||N/A|